Literature DB >> 21289430

Optineurin, a multifunctional protein involved in glaucoma, amyotrophic lateral sclerosis and antiviral signalling.

Ghanshyam Swarup1, Ananthamurthy Nagabhushana.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21289430     DOI： 10.1007/s12038-010-0056-9

Source DB:  PubMed          Journal:  J Biosci        ISSN： 0250-5991            Impact factor:   1.826


× No keyword cloud information.
  28 in total

1.  FIP-2, a coiled-coil protein, links Huntingtin to Rab8 and modulates cellular morphogenesis.

Authors:  K Hattula; J Peränen
Journal:  Curr Biol       Date:  2000 Dec 14-28       Impact factor: 10.834

2.  Adult-onset primary open-angle glaucoma caused by mutations in optineurin.

Authors:  Tayebeh Rezaie; Anne Child; Roger Hitchings; Glen Brice; Lauri Miller; Miguel Coca-Prados; Elise Héon; Theodore Krupin; Robert Ritch; Donald Kreutzer; R Pitts Crick; Mansoor Sarfarazi
Journal:  Science       Date:  2002-02-08       Impact factor: 47.728

Review 3.  Roles for NF-kappaB in nerve cell survival, plasticity, and disease.

Authors:  M P Mattson; M K Meffert
Journal:  Cell Death Differ       Date:  2006-05       Impact factor: 15.828

4.  Identification of genes that are linked with optineurin expression using a combined RNAi--microarray approach.

Authors:  Nicole Weisschuh; Marcel V Alavi; Michael Bonin; Bernd Wissinger
Journal:  Exp Eye Res       Date:  2007-06-27       Impact factor: 3.467

5.  Identification of a novel adult-onset primary open-angle glaucoma (POAG) gene on 5q22.1.

Authors:  Sharareh Monemi; George Spaeth; Alexander DaSilva; Samuel Popinchalk; Elena Ilitchev; Jeffrey Liebmann; Robert Ritch; Elise Héon; Ronald Pitts Crick; Anne Child; Mansoor Sarfarazi
Journal:  Hum Mol Genet       Date:  2005-01-27       Impact factor: 6.150

6.  Identification of a gene that causes primary open angle glaucoma.

Authors:  E M Stone; J H Fingert; W L Alward; T D Nguyen; J R Polansky; S L Sunden; D Nishimura; A F Clark; A Nystuen; B E Nichols; D A Mackey; R Ritch; J W Kalenak; E R Craven; V C Sheffield
Journal:  Science       Date:  1997-01-31       Impact factor: 47.728

7.  Impairment of protein trafficking upon overexpression and mutation of optineurin.

Authors:  BumChan Park; Hongyu Ying; Xiang Shen; Jeong-Seok Park; Ye Qiu; Rajalekshmy Shyam; Beatrice Y J T Yue
Journal:  PLoS One       Date:  2010-07-12       Impact factor: 3.240

Review 8.  Molecular complexity of primary open angle glaucoma: current concepts.

Authors:  Kunal Ray; Suddhasil Mookherjee
Journal:  J Genet       Date:  2009-12       Impact factor: 1.166

9.  Optineurin negatively regulates TNFalpha- induced NF-kappaB activation by competing with NEMO for ubiquitinated RIP.

Authors:  Guozhi Zhu; Chuan-Jin Wu; Yongge Zhao; Jonathan D Ashwell
Journal:  Curr Biol       Date:  2007-08-21       Impact factor: 10.834

10.  NF-kappaB mediates tumor necrosis factor alpha-induced expression of optineurin, a negative regulator of NF-kappaB.

Authors:  Cherukuri Sudhakar; Ananthamurthy Nagabhushana; Nishant Jain; Ghanshyam Swarup
Journal:  PLoS One       Date:  2009-04-02       Impact factor: 3.240
View more
  4 in total

1.  From the Cover: Alterations in Optineurin Expression and Localization in Pre-clinical Parkinson's Disease Models.

Authors:  John Pierce Wise; Jason Cannon
Journal:  Toxicol Sci       Date:  2016-07-29       Impact factor: 4.849

2.  The TBK1-binding domain of optineurin promotes type I interferon responses.

Authors:  Netra Pal Meena; Guozhi Zhu; Paul R Mittelstadt; Maria Letizia Giardino Torchia; Marie Pourcelot; Damien Arnoult; Jonathan D Ashwell; Ivana Munitic
Journal:  FEBS Lett       Date:  2016-05-04       Impact factor: 4.124

3.  Amyotrophic lateral sclerosis: update and new developments.

Authors:  Ashley J Pratt; Elizabeth D Getzoff; J Jefferson P Perry
Journal:  Degener Neurol Neuromuscul Dis       Date:  2012-02

4.  E3-14.7K is recruited to TNF-receptor 1 and blocks TNF cytolysis independent from interaction with optineurin.

Authors:  Laura Klingseisen; Martin Ehrenschwender; Ulrike Heigl; Harald Wajant; Thomas Hehlgans; Stefan Schütze; Wulf Schneider-Brachert
Journal:  PLoS One       Date:  2012-06-04       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.